Venetoclax And Other New Kids On The Block Shine At ASH
Emerging drugs for chronic lymphocytic leukemia include Roche/AbbVie’s venetoclax (ABT-199), Acerta’s ACP-196, Merck’s Keytruda and MorPhoSys’ MOR208.
You may also be interested in...
AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.
A CAR-T late breaker from Kite Pharma and sickle cell disease updates from recently acquired Oklahoma biotech, Selxys, lead Scrip's handpicked top 10 data presentations you shouldn't miss at this year's American Society for Hematology annual meeting, held in San Diego, Dec. 2-6.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.